



## Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November

November 3, 2020

NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three upcoming investor conferences in November:

### **29<sup>th</sup> Annual Credit Suisse Virtual Healthcare Conference**

**Date:** Tuesday, November 10

**Presentation Time:** 1:15 p.m. ET

### **H.C. Wainwright & Co. 6<sup>th</sup> Annual Israel Conference**

**Date:** Thursday, November 12

**Presentation Time:** 11:00 a.m. ET

### **Jefferies Virtual London Healthcare Conference**

**Date:** Tuesday, November 17- Thursday, November 19

Management will be available for one-on-one meetings.

Live audio webcasts of the Credit Suisse and H.C. Wainwright presentations will be available under "Events and Presentations" in the Investors section of the Company's website at [www.allenapharma.com](http://www.allenapharma.com). Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

### **About Allena Pharmaceuticals**

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346, currently being evaluated in a Phase 1 clinical trial, for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease.

### **Investor Contact**

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

[hannah.deresiewicz@sternir.com](mailto:hannah.deresiewicz@sternir.com)

### **Media Contact**

Adam Daley

Berry & Company Public Relations

212-253-8881

[adaley@berrypr.com](mailto:adaley@berrypr.com)



Source: Allena Pharmaceuticals, Inc.